Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04945824 · ClinicalTrials.gov registry record · Early Phase 1
A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
A Early Phase 1 study, sponsored by Ocular Therapeutix.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT04945824 is a Early Phase 1 study that was terminated before completion, run by Ocular Therapeutix. The registered enrollment target is 2 participants.
The verdict
NCT04945824, a Early Phase 1 study, was terminated before completion, sponsored by Ocular Therapeutix.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in tears. Each subject's participation is expected to last for approximately 1 month from the DEXTENZA insertion.
Interventions
- DRUG Dexamethasone Ophthalmic
- DEVICE Dilator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2022-11-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04945824
The ClinicalTrials.gov registry entry for NCT04945824 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone Ophthalmic is the first listed.
NCT04945824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04945824 about?
NCT04945824 is a clinical study titled "A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects". This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in tears. Each subject's participation is expected to last for approximat...
What is the current status of trial NCT04945824?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2021-06-01. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT04945824?
The interventions under investigation include: Dexamethasone Ophthalmic (DRUG), Dilator (DEVICE).
Who is sponsoring clinical trial NCT04945824?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.